F
Frédéric Charlotte
Researcher at University of Paris
Publications - 315
Citations - 27482
Frédéric Charlotte is an academic researcher from University of Paris. The author has contributed to research in topics: Liver biopsy & Histiocytosis. The author has an hindex of 75, co-authored 295 publications receiving 24972 citations. Previous affiliations of Frédéric Charlotte include Centre national de la recherche scientifique & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
Vlad Ratziu,J. Massard,Frédéric Charlotte,Djamila Messous,Françoise Imbert-Bismut,L. Bonyhay,Mohamed Tahiri,Mona Munteanu,Dominique Thabut,Jean François Cadranel,Brigitte Le Bail,Victor de Ledinghen,Thierry Poynard +12 more
TL;DR: In patients with NAFLD, FibroTest, a simple and non-invasive quantitative estimate of liver fibrosis reliably predicts advanced fibrosis.
Journal ArticleDOI
Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis
Vlad Ratziu,Luminita Bonyhay,Vincent Di Martino,Frédéric Charlotte,Lucas Cavallaro,Marie-Hélène Sayegh-Tainturier,Philippe Giral,André Grimaldi,Pierre Opolon,Thierry Poynard +9 more
TL;DR: It is concluded that obesity‐related cirrhosis should now be recognized as a distinct entity that can cause severe liver disease and death.
Journal ArticleDOI
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
Julien Haroche,Fleur Cohen-Aubart,Jean-François Emile,Laurent Arnaud,Philippe Maksud,Frédéric Charlotte,Philippe Cluzel,Aurélie Drier,Baptiste Hervier,Neila Benameur,Sophie Besnard,Jean Donadieu,Zahir Amoura +12 more
TL;DR: Treatment with vemurafenib, a newly approved BRAF inhibitor, should be considered for patients with severe and refractory BRAFV600E histiocytoses, particularly when the disease is life-threatening.
Journal ArticleDOI
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
Raluca Pais,Frédéric Charlotte,Larissa Fedchuk,Pierre Bedossa,Pascal Lebray,Thierry Poynard,Vlad Ratziu +6 more
TL;DR: A substantial proportion of patients with NAFL can progress towards well-defined NASH with bridging fibrosis, especially if metabolic risk factors deteriorate, and current monitoring practices of these patients should be revised.
Diagnostic Value of Biochemical Mar ker s (Fibr oTest-Fibr oSURE) for the pr ediction of Liver Fibr osis in patients with Non-Alcoholic Fatty Liver Disease
Vlad Ratziu,J. Massard,Frédéric Charlotte,Djamila Messous,Françoise Imbert-Bismut,L. Bonyhay,Mohamed Tahiri,Dominique Thabut,Jean François Cadranel,Victor de Lédinghen,Thierry Poynard,Biochemistry Hôpital La Pitié +11 more